About this Medicine article
Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical Trial by Bruce Ettinger is a Medicine article available to read on EtoBox.
## Context: Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known. ## Objective: To determine the effect of raloxifene therapy on risk of vertebral and nonvertebral fractures. ## Design: The multiple outcomes of raloxifene evaluation (more) study, a multicenter, randomized, blinded, placebo-controlled trial. ## Setting and participants: A total of 7705 women aged 31 to 80 years in 25 countries who had been postmenopausal for at least 2 years and who met world health organization criteria for having osteoporosis. the study began in 1994 and had up to 36 months of follow-up for primary efficacy measurements and nonserious adverse events and up to 40 months of follow-up for serious adverse events. ## Interventions: Participants were randomized to 60 mg/d or 120 mg/d of raloxifene or to identically appearing placebo pills; in addition, all women received supplemental calcium and cholecalciferol. ## Main outcome measures: Incident vertebral fracture was determined radiographically at baseline and at scheduled 24- and 36-month visits. nonvertebral fracture was ascerta
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Bruce Ettinger
- Publisher
- American Medical Association (AMA)
- Published
- 1999
- Language
- EN
- Field
- Medicine (Health Sciences)